Dr Rejman observed that "You will recall that in summary the Department feels that there is no justification for routine use of recombinant Factor VIII in patients with haemophilia".
Chronology Information
Date:
Chapter/issue
Access to Treatment
Key Person(s)
Dr Andrzej Rejman